5 Comments
 

I think it's time to buy some puts at these all time highs. Limited risk if the bull run continues, but cash in anytime we get taper talk.

 

Go to Finviz.com, look at the stock screener, look at EVERY chart for the Biotech stocks. There are tons that are money printers. http://finviz.com/screener.ashx?v=111&f=ind_biotechnology&o=-change

I don't venture much into stocks under the broader "Healthcare" sector, but dang, STXS was on fire today. And of course, I have to be broke. http://finviz.com/screener.ashx?v=111&f=sec_healthcare&o=-change

Seriously though, look at STXS's chart for today, tell me you couldn't scalp 10% off it even starting at/after 10am.

STXS is big, same for ADHD, SRPT (been liking this since early this year in the mid 20s), the list goes on.

Broad market? Screw that. You can always find a biotech trending up regardless of the cyclicality of the market, and if you're concerned about a market crash, just get some puts on SPDR.

 

I am personally a fan of Qualcomm. I bought it when it was 3% down YTD and have enjoyed a small 8% run since. It's under-performed the S&P this year and is a great play on the shift to to 3G and 4G with its LTE leadership. It's definitely not a stock that's gonna pop any time soon, (it's a 115 billion in market cap after all) but I think the moat is great, and can deliver both revenue growth and earnings over the next few years consistently. Great core large cap holding. Feel free to disagree

Near term catalysts - September iPhone 5S/low end iPhone release, increase in share buyback/capital allocation come analyst day in November.

 

SQM. It got hit hard with the Potash cartel breakup but this stock is much more then that. It is so diversified its management can divert resources away from their Potash division into Iodine or Lithium production

 

Fugiat cumque nemo consequuntur eos eligendi. Soluta laudantium deserunt saepe dolore omnis necessitatibus. Facere iure voluptatum veniam. Natus rerum et recusandae cumque officia. Vitae et perspiciatis aut quia impedit.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (65) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”